Table 1

Patient and tumor characteristics

Patient no.	Age	Sex	Histopathology	TNM	SUV-FLT mean	SUV-FLT max	Ki-67 index
1	57	F	NSCLC	T₁N₁M₀	5.63	8.7	65%
2	53	M	NSCLC	T₂N₁M₀	4.02	5	41%
3	77	F	NSCLC	T₂N₁M₀	3.98	5.3	43%
4	71	F	NSCLC	T₂N₁M₀	2.9	4.4	35%
5	75	M	NSCLC	T₂bN₀M₀	3.06	5.7	54%
6	53	F	NSCLC	T₂N₁M₀	Neg.	Neg.	10%
7	61	M	NSCLC	T₃N₀M₀	4.89	6.8	45%
8	66	M	NSCLC	T₁N₀M₀	3.24	4.7	26%
9	76	M	NSCLC	T₄N₂M₀	3.05	5.2	35%
10	55	M	NSCLC	T₂N₂Mx	3.88	5.6	40%
11	62	F	NSCLC	TxN₀M₀	2.26	3.3	10%
12	55	M	NSCLC	T₁N₁M₀	1.11	1.3	12%
13	51	F	NSCLC	T₂N₂M₁	3.64	6.10	43%
14	60	M	NSCLC	T₄N₁M₀	5.62	8.2	40%
15	56	F	NSCLC	T₃N₃M₀	6.38	10.4	70%
16	67	M	NSCLC (carcinoma in situ)	T₁N₀M₀	Neg.	Neg.	32%
17	66	M	SCLC	T₄N₂M₀	1.69	2.4	20%
18	50	M	Non-Hodgkin’s lymphoma	T₂N₀M₀	2.53	4.2	12%
19	68	M	Colorectal cancer, pulmonary met	rTxN₀M₁	Neg.	Neg.	12%
20	51	M	Renal cell carcinoma, pulmonary met	rTxN₀M₁	2.07	3.4	23%
21	65	M	Renal cell carcinoma, pulmonary met	rTxN₀M₁	1.32	1.9	10%
22	37	F	Osteosarcoma, pulmonary met	TxN₀M₁	0.816	1	1%
23	75	M	Bronchiolitis	-	Neg.	Neg.	0%
24	76	M	2×3 cm nodule, clinical course indicated benign lesion	-	Neg.	Neg.	0%
25	51	F	Tuberculoma	-	Neg.	Neg.	5%
26	59	M	Bronchiolitis	-	Neg.	Neg.	0%
27	69	M	Bronchiolitis	-	Neg.	Neg.	0%
28	67	M	1×2 cm nodule, clinical course indicated benign lesion	-	Neg.	Neg.	0%
29	55	F	Fibroma	-	Neg.	Neg.	0%
30	56	M	Bronchopulmonary chondroma	-	Neg.	Neg.	0%